View DividendThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEvolva Holding 경영진경영진 기준 점검 2/4현재 CEO에 대한 정보가 충분하지 않습니다.핵심 정보 최고경영자n/a총 보수CEO 급여 비율n/aCEO 재임 기간no dataCEO 지분 보유율n/a경영진 평균 재임 기간4.8yrs이사회 평균 재임 기간4yrs최근 경영진 업데이트공시 • Mar 07Evolva Holding SA, Annual General Meeting, Apr 12, 2024Evolva Holding SA, Annual General Meeting, Apr 12, 2024.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.공시 • May 08Evolva Holding SA Announces Management AppointmentsEvolva Holding SA at its annual general meeting held on May 5, 2022, approved elected Andreas Pfluger, a senior leader with broad international experience especially in consumer goods industries, as well as Andreas Weigelt, Board representative of shareholder Veraison, as new members of the Board of Directors. Shareholders further elected Andreas Pfluger as member of the Compensation Committee.Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.공시 • Feb 08Evolva Holding SA Announces Executive ChangesEvolva announced that the Board of Directors has appointed Christian Wichert as new CEO. Christian Wichert has a proven track record of transforming organizations and managing for performance. His broad international experience in Europe as well as North and South America spans across the Specialty Chemicals/Life Sciences, Water and Consumer Packaged Goods industries, among others. As a results-oriened leader he builds high performing teams focused on business delivery. Christian Wichert will take over responsibility of Chief Executive Officer as of February 8. He will present himself to the media and the investment community on occasion of the publication of Evolva's full-year 2021 results on March 10, 2022. Oliver Walker, who played a pivotal role in the company's strategic development and transformation over the last five years, will hand over responsibilities as of February 8, 2022. He will be available to support the company in an advisory role over the next 12 months.분석 기사 • Apr 01Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time BeingThe underwhelming share price performance of Evolva Holding SA ( VTX:EVE ) in the past three years would have...모든 업데이트 보기Recent updates공시 • Jul 16+ 1 more updateEvolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024Evolva Holding SA announced that they will report fiscal year 2023 results on Oct 31, 2024공시 • Mar 07Evolva Holding SA, Annual General Meeting, Apr 12, 2024Evolva Holding SA, Annual General Meeting, Apr 12, 2024.공시 • Feb 02Evolva Holding SA ADR - Sponsored to Be Deleted from OTC EquityEvolva Holding SA American Depositary Receipts - Sponsored will be deleted from OTC Equity effective February 02, 2024, due to ADR /GDR Program Terminated.공시 • Dec 29Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss ExchangeLallemand has completed the acquisition of Swiss biotechnology firm Evolva AG from the holding entity Evolva Holding (SWX:EVE), according to a statement published on December 28, 2023. The deal was wrapped up on December 28, 2023 after shareholders of Evolva Holding AG granted approval on December 21, 2023. Evolva Holding SA will now seek the delisting of its shares from SIX Swiss Exchange.공시 • Nov 23Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million on November 21, 2023. The purchase price is set at CHF 20 million, subject to customary post-signing/completion adjustments and in addition, Evolva Holding SA and Danstar Ferment AG have entered into an earn-out agreement providing for additional future contingent purchase price payments of up to CHF 10 million, depending on the achievement of certain product-based sales targets over the next 18 months. Evolva's Board of Directors unanimously supports the transaction and recommends approval of the transaction to its shareholders. Evolva will invite shareholders to an extraordinary shareholders’ meeting (EGM) in the coming days. The EGM is expected to be held still this year to ask shareholders to approve the transaction and Evolva’s liquidation and to resolve on the delisting of Evolva from SIX Swiss Exchange. The net proceeds from the transaction will be distributed to the shareholders of Evolva Holding SA after satisfaction of all creditor claims and the warranty periods of the SPA have lapsed.New Risk • Nov 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CHF6.01m (US$6.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (CHF6.01m market cap, or US$6.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CHF10m net loss in 2 years).분석 기사 • Nov 21We Think Evolva Holding (VTX:EVE) Has A Fair Chunk Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Nov 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CHF21.8m market cap, or US$24.2m).New Risk • Sep 28New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF14.1m market cap, or US$15.4m).New Risk • Sep 13New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF11.0m market cap, or US$12.4m).공시 • Sep 07Evolva Receives Approval for Veri-Te Resveratrol in ThailandEvolva has received approval for its Veri-te Resveratrol from the THAI Food and Drug Administration for use as an ingredient in dietary supplements. This approval is further testimony to Evolva's market expansion activities. Thailand will be the fifth country in South-East Asia after the Philippines, Malaysia, Vietnam and Taiwan where Veri-te Resveratrol is available for use in foods and dietary supplements. The approval was obtained with support of Breko and Brenntag Ingredients (Thailand) Public Company Limited. long-term partner Breko is a supplier of products for the food and beverage industry as well as for food supplements, functional food and cosmetic products. Breko and Brenntag ingredients (Thailand) Public Company Limited have been working together in Thailand for many years, bringing innovative ingredients from Europe to the region. The launch, in the format of a technical seminar, is scheduled at Vitafoods ASIA which will take place from 20 - 22 September 2023 in Bangkok, Thailand. This is an important tradeshow for the nutraceutical and food and beverage industry in the region.공시 • Jul 25Evolva Receives FDA Approval for Veri-teTM Resveratrol in TaiwanEvolva has received approval for its Veri-teTM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements. The approval is an important milestone as it opens up Taiwan as a further South-East Asian market after the Philippines, Malaysia and Vietnam where Veri-teTM Resveratrol is already available for use in foods and dietary supplements. The approval was obtained in close partnership with Champion Co. Ltd., Evolva's Taiwanese distribution partner, who supported Evolva throughout the registration process. Champion Co. Ltd. will also accompany market introduction. The launch is scheduled for 28th of July in the format of a technical seminar during Bio Asia Taiwan inTaipei, a key tradeshow in the region.분석 기사 • Jun 09Would Evolva Holding (VTX:EVE) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • May 05Evolva Holding SA (VTX:EVE) Screens Well But There Might Be A CatchThere wouldn't be many who think Evolva Holding SA's ( VTX:EVE ) price-to-sales (or "P/S") ratio of 4.4x is worth a...Reported Earnings • Mar 10Full year 2022 earnings released: CHF0.04 loss per share (vs CHF0.047 loss in FY 2021)Full year 2022 results: CHF0.04 loss per share. Revenue: CHF15.5m (up 57% from FY 2021). Net loss: CHF43.4m (loss widened 5.1% from FY 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Chemicals industry in Switzerland.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 27First half 2022 earnings released: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021)First half 2022 results: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021). Revenue: CHF8.13m (up 28% from 1H 2021). Net loss: CHF28.9m (loss widened 14% from 1H 2021). Over the next year, revenue is forecast to grow 67%, compared to a 12% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 20% per year and the company’s share price has also fallen by 20% per year.공시 • Aug 26Evolva Holding SA Provides Revenue Guidance for the Full Year 2022 and 2025Evolva Holding SA provided revenue guidance for the full year 2022 and 2025. Revenue growth of 50% at constant currencies to CHF 15 million in 2022 expected, with positive double-digit gross contribution margin. The company aims to achieve an annual revenue growth of 40% to 60% in the coming years and targets to reach a revenue level of CHF 45 million to CHF 50 million in 2025.공시 • Aug 25+ 1 more updateEvolva Holding SA to Report Fiscal Year 2022 Results on Mar 09, 2023Evolva Holding SA announced that they will report fiscal year 2022 results on Mar 09, 2023공시 • May 25Evolva Holding SA announced that it has received CHF 6.3226 million in fundingEvolva Holding SA announced a private placement of 62,600,000 common shares at a price of CHF 0.101 per share for gross proceeds of CHF 6,322,600 on May 24, 2022. The transaction included participation from long-term oriented institutional investors, selected members of the Board of Directors and management for CHF 1,000,000.공시 • May 08Evolva Holding SA Announces Management AppointmentsEvolva Holding SA at its annual general meeting held on May 5, 2022, approved elected Andreas Pfluger, a senior leader with broad international experience especially in consumer goods industries, as well as Andreas Weigelt, Board representative of shareholder Veraison, as new members of the Board of Directors. Shareholders further elected Andreas Pfluger as member of the Compensation Committee.Price Target Changed • Apr 27Price target decreased to CHF0.21Down from CHF0.26, the current price target is an average from 3 analysts. New target price is 100% above last closing price of CHF0.11. Stock is down 45% over the past year. The company is forecast to post a net loss per share of CHF0.02 next year compared to a net loss per share of CHF0.047 last year.Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.분석 기사 • Mar 22Is Evolva Holding (VTX:EVE) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Price Target Changed • Mar 14Price target decreased to CHF0.23Down from CHF0.27, the current price target is an average from 3 analysts. New target price is 90% above last closing price of CHF0.12. Stock is down 41% over the past year. The company is forecast to post a net loss per share of CHF0.013 next year compared to a net loss per share of CHF0.047 last year.Reported Earnings • Mar 12Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: CHF0.05 loss per share (down from CHF0.038 loss in FY 2020). Revenue: CHF9.88m (up 31% from FY 2020). Net loss: CHF41.3m (loss widened 38% from FY 2020). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 140%, compared to a 11% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 22% per year.공시 • Feb 08Evolva Holding SA Announces Executive ChangesEvolva announced that the Board of Directors has appointed Christian Wichert as new CEO. Christian Wichert has a proven track record of transforming organizations and managing for performance. His broad international experience in Europe as well as North and South America spans across the Specialty Chemicals/Life Sciences, Water and Consumer Packaged Goods industries, among others. As a results-oriened leader he builds high performing teams focused on business delivery. Christian Wichert will take over responsibility of Chief Executive Officer as of February 8. He will present himself to the media and the investment community on occasion of the publication of Evolva's full-year 2021 results on March 10, 2022. Oliver Walker, who played a pivotal role in the company's strategic development and transformation over the last five years, will hand over responsibilities as of February 8, 2022. He will be available to support the company in an advisory role over the next 12 months.Breakeven Date Change • Jan 21Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.공시 • Dec 28Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SAEvolva Holding SA announced that it has entered into an agreement with returning investor Nice & Green SA for a private placement of convertible securities for gross proceeds of CHF 12 million on December 27, 2021. The transaction will be completed in multiple tranches. The transaction is expected to close by the end of 2023. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume during the six trading days preceding the conversion.분석 기사 • Dec 01Is Evolva Holding (VTX:EVE) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Aug 29First half 2021 earnings released: CHF0.03 loss per share (vs CHF0.02 loss in 1H 2020)The company reported a mediocre first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF6.38m (up 61% from 1H 2020). Net loss: CHF25.4m (loss widened 88% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.공시 • May 17Evolva Holding SA announced that it expects to receive CHF 20 million in funding from Nice & Green SAEvolva Holding SA (SWX:EVE) announced that it has entered into an agreement with returning investor Nice & Green SA for a private placement of convertible securities for gross proceeds of CHF 20 million on May 17, 2021. The transaction will be completed in multiple tranches. The transaction is expected to close by the end of 2022. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume during the six trading days preceding the conversion.분석 기사 • Apr 01Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time BeingThe underwhelming share price performance of Evolva Holding SA ( VTX:EVE ) in the past three years would have...Executive Departure • Mar 10Chief Financial Officer has left the companyOn the 2nd of March, Andre Pennartz's tenure as Chief Financial Officer ended after 1.1 years in the role. We don't have any record of a personal shareholding under Andre's name. A total of 3 executives have left over the last 12 months.Price Target Changed • Mar 03Price target raised to CHF0.32Up from CHF0.29, the current price target is an average from 2 analysts. The new target price is 43% above the current share price of CHF0.22. As of last close, the stock is down 2.6% over the past year.Analyst Estimate Surprise Post Earnings • Mar 03Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 28%. Earnings per share (EPS) exceeded analyst estimates by 38%. Over the next year, revenue is forecast to grow 59%, compared to a 7.6% growth forecast for the Chemicals industry in Switzerland.공시 • Mar 03Evolva Announces Management ChangesEvolva announced that André Pennartz, CFO of Evolva, is leaving the company for personal reasons with immediate effect. Oliver Walker will take on the role of CFO ad interim until a successor is appointed.Reported Earnings • Mar 02Full year 2020 earnings released: CHF0.038 loss per share (vs CHF0.028 loss in FY 2019)Full year 2020 results: Net loss: CHF29.9m (loss widened 38% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.분석 기사 • Feb 13Evolva Holding's (VTX:EVE) Shareholders Are Down 70% On Their SharesWhile it may not be enough for some shareholders, we think it is good to see the Evolva Holding SA ( VTX:EVE ) share...공시 • Jan 21Evolva Launches L-Arabinose, a Natural Sugar Blocker and Reducing SugarEvolva launched L-arabinose (previously known as EVE-X157/Z4), a natural sugar blocker used in food and beverages and reducing sugar applied in food processing. As people around the world continue to strive to live a healthier lifestyle, they are committed to helping their customers create healthier, more sustainable solutions. Studies show that L-arabinose as sugar blocker can support healthy blood sugar levels and weight management. It also has potential application as a prebiotic. As reducing sugar, L-arabinose is also frequently applied in the production of savoury flavors such as chicken and beef. Made by fermentation, Evolva's L-arabinose is fully renewable and sustainable, it has a high-purity level (>99%) and no hydrochloric acid is used in the manufacturing process. L-Arabinose is FEMA GRAS approved for use in food and beverages. L-Arabinose taste profile is well-suited for use in products such as yogurt, chocolate, soft drinks, ice cream, cereal, power bars and confectionary. With a wide range of applications, L-arabinose has a current market value of CHF 250 million, which is expected to grow by at least 5% per annum. Evolva is having commercial discussions with major customers, which include first supply volumes for 2021.Is New 90 Day High Low • Jan 20New 90-day high: CHF0.24The company is up 11% from its price of CHF0.22 on 22 October 2020. The Swiss market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.분석 기사 • Dec 21We're Keeping An Eye On Evolva Holding's (VTX:EVE) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...공시 • Nov 06Evolva Holding Sa Appoints Gerhard Lobmaier as Chief Operations Officer, Effective January 1, 2021Evolva Holding SA announced that Effective January 1, 2021, Gerhard Lobmaier is appointed Evolva's Chief Operations Officer. In his role, he will lead the manufacturing and supply chain functions, supporting the optimization of the CMO network for Evolva, thus increasing security of supply and realizing cost savings. Prior to this appointment, he served in several global functions at Cognis and BASF.Is New 90 Day High Low • Oct 14New 90-day low: CHF0.23The company is down 17% from its price of CHF0.27 on 16 July 2020. The Swiss market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.공시 • Oct 14Processa Pharmaceuticals, Inc. Appoints Michael Floyd as Chief Operating OfficerProcessa Pharmaceuticals Inc. announced the appointment of Michael Floyd as the Company's Chief Operating Officer. Floyd is a serial entrepreneur who, over the last 15 years, has formed and been a senior executive in several life science organizations focused on the development of products to treat infectious and rare diseases, as well as the development of oncology drugs. He founded the early stage enterprise Neurologic, that in-licensed technology from the NIH for a diagnostic test for Alzheimer's disease. In 2006 he served as the CEO for the North American subsidiary of Arpida Ltd. and organized the phase 3 program for the NDA submission of an MRSA drug. Then after joining Gentium, SpA in 2011, he led the US efforts to remediate the NDA for defibrotide. More recently, Mr. Floyd co-founded Elion Oncology which licensed PCS6422 to Processa.공시 • Aug 26Evolva Holding SA to Report Fiscal Year 2020 Results on Feb 25, 2021Evolva Holding SA announced that they will report fiscal year 2020 results at 5:01 AM, GMT Standard Time on Feb 25, 2021공시 • Jun 30Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SAEvolva Holding SA (SWX:EVE) announced that it has entered into an agreement with Nice & Green SA for a private placement of convertible securities for gross proceeds of up to CHF 12 million on June 29, 2020. The transaction will be completed in multiple tranches. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume on SIX during the six trading days preceding the conversion.CEOEvolva Holding에는 CEO가 없거나 해당 데이터가 없습니다.리더십 팀이름직위재임 기간보수지분Gerhard LobmaierChief Operations Officer3.3yrs데이터 없음데이터 없음Thomas SchneckenburgerHead of Investor & Corporate Relationsno data데이터 없음데이터 없음Philipp FrechGeneral Counsel & Secretary of the Board2.3yrs데이터 없음데이터 없음Anne De VosHead of Salesno data데이터 없음데이터 없음Astrid SchaferHead of Innovation6.3yrs데이터 없음데이터 없음Luc GrunerExecutive Officer6.8yrs데이터 없음데이터 없음더 보기4.8yrs평균 재임 기간56.5yo평균 나이경험이 풍부한 관리: EVE의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.8 년).이사회 구성원이름직위재임 기간보수지분Beat In-AlbonVice-Chairman of the Board4yrsCHF 160.00k0.21% CHF 15.5kKarl-Heinz AltmannMember of Scientific Advisory Boardno data데이터 없음데이터 없음Jay KeaslingMember of Scientific Advisory Boardno data데이터 없음데이터 없음Vincent MartinMember of Scientific Advisory Boardno data데이터 없음데이터 없음Jörg BohlmannMember of Scientific Advisory Board8.7yrs데이터 없음데이터 없음Birger MøllerMember of Scientific Advisory Boardno data데이터 없음데이터 없음Karsten KristiansenMember of Scientific Advisory Boardno data데이터 없음데이터 없음Stephan SchindlerChairman of the Board4yrsCHF 95.00k0.15% CHF 10.8k더 보기4.0yrs평균 재임 기간71yo평균 나이경험이 풍부한 이사회: EVE의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4 년).View Ownership기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/04/26 07:15종가2024/04/26 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Evolva Holding SA는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sebastian BrayBerenbergSara WelfordEdison Investment ResearchMartin VoegtliResearch Partners AG1명의 분석가 더 보기
공시 • Mar 07Evolva Holding SA, Annual General Meeting, Apr 12, 2024Evolva Holding SA, Annual General Meeting, Apr 12, 2024.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • May 08Evolva Holding SA Announces Management AppointmentsEvolva Holding SA at its annual general meeting held on May 5, 2022, approved elected Andreas Pfluger, a senior leader with broad international experience especially in consumer goods industries, as well as Andreas Weigelt, Board representative of shareholder Veraison, as new members of the Board of Directors. Shareholders further elected Andreas Pfluger as member of the Compensation Committee.
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
공시 • Feb 08Evolva Holding SA Announces Executive ChangesEvolva announced that the Board of Directors has appointed Christian Wichert as new CEO. Christian Wichert has a proven track record of transforming organizations and managing for performance. His broad international experience in Europe as well as North and South America spans across the Specialty Chemicals/Life Sciences, Water and Consumer Packaged Goods industries, among others. As a results-oriened leader he builds high performing teams focused on business delivery. Christian Wichert will take over responsibility of Chief Executive Officer as of February 8. He will present himself to the media and the investment community on occasion of the publication of Evolva's full-year 2021 results on March 10, 2022. Oliver Walker, who played a pivotal role in the company's strategic development and transformation over the last five years, will hand over responsibilities as of February 8, 2022. He will be available to support the company in an advisory role over the next 12 months.
분석 기사 • Apr 01Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time BeingThe underwhelming share price performance of Evolva Holding SA ( VTX:EVE ) in the past three years would have...
공시 • Jul 16+ 1 more updateEvolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024Evolva Holding SA announced that they will report fiscal year 2023 results on Oct 31, 2024
공시 • Mar 07Evolva Holding SA, Annual General Meeting, Apr 12, 2024Evolva Holding SA, Annual General Meeting, Apr 12, 2024.
공시 • Feb 02Evolva Holding SA ADR - Sponsored to Be Deleted from OTC EquityEvolva Holding SA American Depositary Receipts - Sponsored will be deleted from OTC Equity effective February 02, 2024, due to ADR /GDR Program Terminated.
공시 • Dec 29Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss ExchangeLallemand has completed the acquisition of Swiss biotechnology firm Evolva AG from the holding entity Evolva Holding (SWX:EVE), according to a statement published on December 28, 2023. The deal was wrapped up on December 28, 2023 after shareholders of Evolva Holding AG granted approval on December 21, 2023. Evolva Holding SA will now seek the delisting of its shares from SIX Swiss Exchange.
공시 • Nov 23Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million on November 21, 2023. The purchase price is set at CHF 20 million, subject to customary post-signing/completion adjustments and in addition, Evolva Holding SA and Danstar Ferment AG have entered into an earn-out agreement providing for additional future contingent purchase price payments of up to CHF 10 million, depending on the achievement of certain product-based sales targets over the next 18 months. Evolva's Board of Directors unanimously supports the transaction and recommends approval of the transaction to its shareholders. Evolva will invite shareholders to an extraordinary shareholders’ meeting (EGM) in the coming days. The EGM is expected to be held still this year to ask shareholders to approve the transaction and Evolva’s liquidation and to resolve on the delisting of Evolva from SIX Swiss Exchange. The net proceeds from the transaction will be distributed to the shareholders of Evolva Holding SA after satisfaction of all creditor claims and the warranty periods of the SPA have lapsed.
New Risk • Nov 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CHF6.01m (US$6.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (CHF6.01m market cap, or US$6.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CHF10m net loss in 2 years).
분석 기사 • Nov 21We Think Evolva Holding (VTX:EVE) Has A Fair Chunk Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Nov 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CHF21.8m market cap, or US$24.2m).
New Risk • Sep 28New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF14.1m market cap, or US$15.4m).
New Risk • Sep 13New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF11.0m market cap, or US$12.4m).
공시 • Sep 07Evolva Receives Approval for Veri-Te Resveratrol in ThailandEvolva has received approval for its Veri-te Resveratrol from the THAI Food and Drug Administration for use as an ingredient in dietary supplements. This approval is further testimony to Evolva's market expansion activities. Thailand will be the fifth country in South-East Asia after the Philippines, Malaysia, Vietnam and Taiwan where Veri-te Resveratrol is available for use in foods and dietary supplements. The approval was obtained with support of Breko and Brenntag Ingredients (Thailand) Public Company Limited. long-term partner Breko is a supplier of products for the food and beverage industry as well as for food supplements, functional food and cosmetic products. Breko and Brenntag ingredients (Thailand) Public Company Limited have been working together in Thailand for many years, bringing innovative ingredients from Europe to the region. The launch, in the format of a technical seminar, is scheduled at Vitafoods ASIA which will take place from 20 - 22 September 2023 in Bangkok, Thailand. This is an important tradeshow for the nutraceutical and food and beverage industry in the region.
공시 • Jul 25Evolva Receives FDA Approval for Veri-teTM Resveratrol in TaiwanEvolva has received approval for its Veri-teTM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements. The approval is an important milestone as it opens up Taiwan as a further South-East Asian market after the Philippines, Malaysia and Vietnam where Veri-teTM Resveratrol is already available for use in foods and dietary supplements. The approval was obtained in close partnership with Champion Co. Ltd., Evolva's Taiwanese distribution partner, who supported Evolva throughout the registration process. Champion Co. Ltd. will also accompany market introduction. The launch is scheduled for 28th of July in the format of a technical seminar during Bio Asia Taiwan inTaipei, a key tradeshow in the region.
분석 기사 • Jun 09Would Evolva Holding (VTX:EVE) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • May 05Evolva Holding SA (VTX:EVE) Screens Well But There Might Be A CatchThere wouldn't be many who think Evolva Holding SA's ( VTX:EVE ) price-to-sales (or "P/S") ratio of 4.4x is worth a...
Reported Earnings • Mar 10Full year 2022 earnings released: CHF0.04 loss per share (vs CHF0.047 loss in FY 2021)Full year 2022 results: CHF0.04 loss per share. Revenue: CHF15.5m (up 57% from FY 2021). Net loss: CHF43.4m (loss widened 5.1% from FY 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Chemicals industry in Switzerland.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 27First half 2022 earnings released: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021)First half 2022 results: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021). Revenue: CHF8.13m (up 28% from 1H 2021). Net loss: CHF28.9m (loss widened 14% from 1H 2021). Over the next year, revenue is forecast to grow 67%, compared to a 12% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 20% per year and the company’s share price has also fallen by 20% per year.
공시 • Aug 26Evolva Holding SA Provides Revenue Guidance for the Full Year 2022 and 2025Evolva Holding SA provided revenue guidance for the full year 2022 and 2025. Revenue growth of 50% at constant currencies to CHF 15 million in 2022 expected, with positive double-digit gross contribution margin. The company aims to achieve an annual revenue growth of 40% to 60% in the coming years and targets to reach a revenue level of CHF 45 million to CHF 50 million in 2025.
공시 • Aug 25+ 1 more updateEvolva Holding SA to Report Fiscal Year 2022 Results on Mar 09, 2023Evolva Holding SA announced that they will report fiscal year 2022 results on Mar 09, 2023
공시 • May 25Evolva Holding SA announced that it has received CHF 6.3226 million in fundingEvolva Holding SA announced a private placement of 62,600,000 common shares at a price of CHF 0.101 per share for gross proceeds of CHF 6,322,600 on May 24, 2022. The transaction included participation from long-term oriented institutional investors, selected members of the Board of Directors and management for CHF 1,000,000.
공시 • May 08Evolva Holding SA Announces Management AppointmentsEvolva Holding SA at its annual general meeting held on May 5, 2022, approved elected Andreas Pfluger, a senior leader with broad international experience especially in consumer goods industries, as well as Andreas Weigelt, Board representative of shareholder Veraison, as new members of the Board of Directors. Shareholders further elected Andreas Pfluger as member of the Compensation Committee.
Price Target Changed • Apr 27Price target decreased to CHF0.21Down from CHF0.26, the current price target is an average from 3 analysts. New target price is 100% above last closing price of CHF0.11. Stock is down 45% over the past year. The company is forecast to post a net loss per share of CHF0.02 next year compared to a net loss per share of CHF0.047 last year.
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
분석 기사 • Mar 22Is Evolva Holding (VTX:EVE) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Price Target Changed • Mar 14Price target decreased to CHF0.23Down from CHF0.27, the current price target is an average from 3 analysts. New target price is 90% above last closing price of CHF0.12. Stock is down 41% over the past year. The company is forecast to post a net loss per share of CHF0.013 next year compared to a net loss per share of CHF0.047 last year.
Reported Earnings • Mar 12Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: CHF0.05 loss per share (down from CHF0.038 loss in FY 2020). Revenue: CHF9.88m (up 31% from FY 2020). Net loss: CHF41.3m (loss widened 38% from FY 2020). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 140%, compared to a 11% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 22% per year.
공시 • Feb 08Evolva Holding SA Announces Executive ChangesEvolva announced that the Board of Directors has appointed Christian Wichert as new CEO. Christian Wichert has a proven track record of transforming organizations and managing for performance. His broad international experience in Europe as well as North and South America spans across the Specialty Chemicals/Life Sciences, Water and Consumer Packaged Goods industries, among others. As a results-oriened leader he builds high performing teams focused on business delivery. Christian Wichert will take over responsibility of Chief Executive Officer as of February 8. He will present himself to the media and the investment community on occasion of the publication of Evolva's full-year 2021 results on March 10, 2022. Oliver Walker, who played a pivotal role in the company's strategic development and transformation over the last five years, will hand over responsibilities as of February 8, 2022. He will be available to support the company in an advisory role over the next 12 months.
Breakeven Date Change • Jan 21Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
공시 • Dec 28Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SAEvolva Holding SA announced that it has entered into an agreement with returning investor Nice & Green SA for a private placement of convertible securities for gross proceeds of CHF 12 million on December 27, 2021. The transaction will be completed in multiple tranches. The transaction is expected to close by the end of 2023. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume during the six trading days preceding the conversion.
분석 기사 • Dec 01Is Evolva Holding (VTX:EVE) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Aug 29First half 2021 earnings released: CHF0.03 loss per share (vs CHF0.02 loss in 1H 2020)The company reported a mediocre first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF6.38m (up 61% from 1H 2020). Net loss: CHF25.4m (loss widened 88% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
공시 • May 17Evolva Holding SA announced that it expects to receive CHF 20 million in funding from Nice & Green SAEvolva Holding SA (SWX:EVE) announced that it has entered into an agreement with returning investor Nice & Green SA for a private placement of convertible securities for gross proceeds of CHF 20 million on May 17, 2021. The transaction will be completed in multiple tranches. The transaction is expected to close by the end of 2022. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume during the six trading days preceding the conversion.
분석 기사 • Apr 01Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time BeingThe underwhelming share price performance of Evolva Holding SA ( VTX:EVE ) in the past three years would have...
Executive Departure • Mar 10Chief Financial Officer has left the companyOn the 2nd of March, Andre Pennartz's tenure as Chief Financial Officer ended after 1.1 years in the role. We don't have any record of a personal shareholding under Andre's name. A total of 3 executives have left over the last 12 months.
Price Target Changed • Mar 03Price target raised to CHF0.32Up from CHF0.29, the current price target is an average from 2 analysts. The new target price is 43% above the current share price of CHF0.22. As of last close, the stock is down 2.6% over the past year.
Analyst Estimate Surprise Post Earnings • Mar 03Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 28%. Earnings per share (EPS) exceeded analyst estimates by 38%. Over the next year, revenue is forecast to grow 59%, compared to a 7.6% growth forecast for the Chemicals industry in Switzerland.
공시 • Mar 03Evolva Announces Management ChangesEvolva announced that André Pennartz, CFO of Evolva, is leaving the company for personal reasons with immediate effect. Oliver Walker will take on the role of CFO ad interim until a successor is appointed.
Reported Earnings • Mar 02Full year 2020 earnings released: CHF0.038 loss per share (vs CHF0.028 loss in FY 2019)Full year 2020 results: Net loss: CHF29.9m (loss widened 38% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
분석 기사 • Feb 13Evolva Holding's (VTX:EVE) Shareholders Are Down 70% On Their SharesWhile it may not be enough for some shareholders, we think it is good to see the Evolva Holding SA ( VTX:EVE ) share...
공시 • Jan 21Evolva Launches L-Arabinose, a Natural Sugar Blocker and Reducing SugarEvolva launched L-arabinose (previously known as EVE-X157/Z4), a natural sugar blocker used in food and beverages and reducing sugar applied in food processing. As people around the world continue to strive to live a healthier lifestyle, they are committed to helping their customers create healthier, more sustainable solutions. Studies show that L-arabinose as sugar blocker can support healthy blood sugar levels and weight management. It also has potential application as a prebiotic. As reducing sugar, L-arabinose is also frequently applied in the production of savoury flavors such as chicken and beef. Made by fermentation, Evolva's L-arabinose is fully renewable and sustainable, it has a high-purity level (>99%) and no hydrochloric acid is used in the manufacturing process. L-Arabinose is FEMA GRAS approved for use in food and beverages. L-Arabinose taste profile is well-suited for use in products such as yogurt, chocolate, soft drinks, ice cream, cereal, power bars and confectionary. With a wide range of applications, L-arabinose has a current market value of CHF 250 million, which is expected to grow by at least 5% per annum. Evolva is having commercial discussions with major customers, which include first supply volumes for 2021.
Is New 90 Day High Low • Jan 20New 90-day high: CHF0.24The company is up 11% from its price of CHF0.22 on 22 October 2020. The Swiss market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.
분석 기사 • Dec 21We're Keeping An Eye On Evolva Holding's (VTX:EVE) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
공시 • Nov 06Evolva Holding Sa Appoints Gerhard Lobmaier as Chief Operations Officer, Effective January 1, 2021Evolva Holding SA announced that Effective January 1, 2021, Gerhard Lobmaier is appointed Evolva's Chief Operations Officer. In his role, he will lead the manufacturing and supply chain functions, supporting the optimization of the CMO network for Evolva, thus increasing security of supply and realizing cost savings. Prior to this appointment, he served in several global functions at Cognis and BASF.
Is New 90 Day High Low • Oct 14New 90-day low: CHF0.23The company is down 17% from its price of CHF0.27 on 16 July 2020. The Swiss market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
공시 • Oct 14Processa Pharmaceuticals, Inc. Appoints Michael Floyd as Chief Operating OfficerProcessa Pharmaceuticals Inc. announced the appointment of Michael Floyd as the Company's Chief Operating Officer. Floyd is a serial entrepreneur who, over the last 15 years, has formed and been a senior executive in several life science organizations focused on the development of products to treat infectious and rare diseases, as well as the development of oncology drugs. He founded the early stage enterprise Neurologic, that in-licensed technology from the NIH for a diagnostic test for Alzheimer's disease. In 2006 he served as the CEO for the North American subsidiary of Arpida Ltd. and organized the phase 3 program for the NDA submission of an MRSA drug. Then after joining Gentium, SpA in 2011, he led the US efforts to remediate the NDA for defibrotide. More recently, Mr. Floyd co-founded Elion Oncology which licensed PCS6422 to Processa.
공시 • Aug 26Evolva Holding SA to Report Fiscal Year 2020 Results on Feb 25, 2021Evolva Holding SA announced that they will report fiscal year 2020 results at 5:01 AM, GMT Standard Time on Feb 25, 2021
공시 • Jun 30Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SAEvolva Holding SA (SWX:EVE) announced that it has entered into an agreement with Nice & Green SA for a private placement of convertible securities for gross proceeds of up to CHF 12 million on June 29, 2020. The transaction will be completed in multiple tranches. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume on SIX during the six trading days preceding the conversion.